INmune Bio Stock Forecast, Price & News

-1.39 (-6.29 %)
(As of 07/23/2021 12:26 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume6,215 shs
Average Volume627,852 shs
Market Capitalization$327.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive INMB News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INmune Bio logo

About INmune Bio

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

566th out of 2,216 stocks

Biological Products, Except Diagnostic Industry

83rd out of 211 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

INmune Bio (NASDAQ:INMB) Frequently Asked Questions

Is INmune Bio a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INmune Bio stock.
View analyst ratings for INmune Bio
or view top-rated stocks.

What stocks does MarketBeat like better than INmune Bio?

Wall Street analysts have given INmune Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but INmune Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for INmune Bio

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) released its earnings results on Tuesday, May, 4th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.05.
View INmune Bio's earnings history

How has INmune Bio's stock price been impacted by Coronavirus (COVID-19)?

INmune Bio's stock was trading at $4.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INMB stock has increased by 331.3% and is now trading at $20.70.
View which stocks have been most impacted by COVID-19

What price target have analysts set for INMB?

4 equities research analysts have issued 12 month price objectives for INmune Bio's stock. Their forecasts range from $15.00 to $42.00. On average, they expect INmune Bio's stock price to reach $28.50 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price.
View analysts' price targets for INmune Bio
or view top-rated stocks among Wall Street analysts.

Who are INmune Bio's key executives?

INmune Bio's management team includes the following people:
  • Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO, Chief Medical Officer & Chairman (Age 65, Pay $300k)
  • Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 51, Pay $300k)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer & Chief Manufacturing Officer (Age 58, Pay $138.2k)
  • Mr. Joshua S. Schoonover Esq., Assoc. Gen. Counsel
  • Dr. Christopher J. Barnum, Director of Neuroscience

Who are some of INmune Bio's key competitors?

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

How do I buy shares of INmune Bio?

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $20.70.

How much money does INmune Bio make?

INmune Bio has a market capitalization of $327.89 million and generates $10,000.00 in revenue each year. The company earns $-12,100,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does INmune Bio have?

INmune Bio employs 5 workers across the globe.

What is INmune Bio's official website?

The official website for INmune Bio is

Where are INmune Bio's headquarters?

INmune Bio is headquartered at 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at (858) 964-3720 or via email at [email protected]

This page was last updated on 7/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.